Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Bickel

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
Cells|October 14, 2022
HIV-1 Infection of Long-Lived Hematopoietic Precursors In Vitro and In VivoSebastian Renelt, Patrizia Schult-Dietrich, Hanna-Mari Baldauf, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|February 17, 2022
[HIV First Diagnoses in Germany in 2014 - A Regional Analysis]Benjamin Thomas Schleenvoigt, Juliane Ankert, Hartmut Stocker, et al.
Infection|May 13, 2020
High effectiveness of recommended first-line antiretroviral therapies in Germany: a nationwide, prospective cohort studyMarkus Bickel, Christian Hoffmann, Eva Wolf, et al.
AIDS (London, England)|December 15, 2010
Boosted protease inhibitors and the electrocardiographic measures of QT and PR durationsElsayed Z Soliman, Jens D Lundgren, Mollie P Roediger, et al.
Infection|May 13, 2020
COVID-19 in people living with human immunodeficiency virus: a case series of 33 patientsGeorg Härter, Christoph D Spinner, Julia Roider, et al.
The Journal of Antimicrobial Chemotherapy|March 6, 2010
Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravirMarkus Bickel, Evrim Anadol, Martin Vogel, et al.
The Journal of Infection|July 9, 2021
Risk factors for IRIS in HIV-associated Pneumocystis-pneumonia following ART initiationGerrit Kann, Nils Wetzstein, Hannah Bielke, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 16, 2019
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT TrialMargaret Johnson, Princy Kumar, Jean-Michel Molina, et al.
Infection|October 30, 2024
Characterising HIV-Indicator conditions among two nationwide long-term cohorts of people living with HIV in Germany (1999-2023)Amrei Krings, Christian Kollan, Daniel Schmidt, et al.
Eclinicalmedicine|October 22, 2024
Prevalence of HIV in people with potential HIV-indicator conditions in Germany: an analysis of data from statutory health insurancesFrederik Valbert, Georg M N Behrens, Markus Bickel, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Cells|October 14, 2022
HIV-1 Infection of Long-Lived Hematopoietic Precursors In Vitro and In VivoSebastian Renelt, Patrizia Schult-Dietrich, Hanna-Mari Baldauf, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|February 17, 2022
[HIV First Diagnoses in Germany in 2014 - A Regional Analysis]Benjamin Thomas Schleenvoigt, Juliane Ankert, Hartmut Stocker, et al.
Infection|May 13, 2020
High effectiveness of recommended first-line antiretroviral therapies in Germany: a nationwide, prospective cohort studyMarkus Bickel, Christian Hoffmann, Eva Wolf, et al.
AIDS (London, England)|December 15, 2010
Boosted protease inhibitors and the electrocardiographic measures of QT and PR durationsElsayed Z Soliman, Jens D Lundgren, Mollie P Roediger, et al.
Infection|May 13, 2020
COVID-19 in people living with human immunodeficiency virus: a case series of 33 patientsGeorg Härter, Christoph D Spinner, Julia Roider, et al.
The Journal of Antimicrobial Chemotherapy|March 6, 2010
Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravirMarkus Bickel, Evrim Anadol, Martin Vogel, et al.
The Journal of Infection|July 9, 2021
Risk factors for IRIS in HIV-associated Pneumocystis-pneumonia following ART initiationGerrit Kann, Nils Wetzstein, Hannah Bielke, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 16, 2019
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT TrialMargaret Johnson, Princy Kumar, Jean-Michel Molina, et al.
Infection|October 30, 2024
Characterising HIV-Indicator conditions among two nationwide long-term cohorts of people living with HIV in Germany (1999-2023)Amrei Krings, Christian Kollan, Daniel Schmidt, et al.
Eclinicalmedicine|October 22, 2024
Prevalence of HIV in people with potential HIV-indicator conditions in Germany: an analysis of data from statutory health insurancesFrederik Valbert, Georg M N Behrens, Markus Bickel, et al.
Pageof 7